Orient Pharma Co., Ltd. (TPEX:4166)

Market Cap	5.44B -17.6%
Revenue (ttm)	1.41B +11.9%
Net Income	196.58M +63.9%
EPS	0.88 +63.9%
Shares Out	223.04M
PE Ratio	27.68
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	369,022
Open	23.40
Previous Close	23.30
Day's Range	23.25 - 24.40
52-Week Range	22.30 - 40.00
Beta	0.12
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About Orient Pharma

Orient Pharma Co., Ltd. engages in the development of new drugs in Taiwan and internationally. It offers cardiovascular drugs, such as Pitator and Tonvasca for lipid suppression, as well as Zulitor, a lipid lowering drug; psychotropic drugs, including Trokendi XR extended, Methydur, and powder and solvent for prolonged-release suspension for injection. The company was founded in 2008 and is based in Taipei, Taiwan.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2008
• Employees: 173
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4166

Financial Performance

In 2025, Orient Pharma's revenue was 1.40 billion, an increase of 14.52% compared to the previous year's 1.22 billion. Earnings were 208.44 million, an increase of 94.12%.